Clinical trials: Drug Drug Interaction Study
Drug Interactions, Neoplasms
A Cross-over Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics (PK) of GSK525762 in Healthy Female Subjects of Non Child Bearing Potential
This is a Phase I, single center, two-part, randomized, open label, cross-over study. Part 1 of this study will evaluate the PK, safety, and tolerability of GSK525762 when administered alone and when co-administered following…
- Trial name
- NCT02706535
- Testing
- GSK525762 Besylate Tablets, Itraconazole 200 mg, Rifampicin 300 mg
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Subjects, Infection, Human Immunodeficiency Virus
GSK1349572 Drug Interaction Study With Protease Inhibitors
A study in healthy volunteers to determine whether there is a drug interaction between GSK1349572 and the HIV protease inhibitors lopinavir/ritonavir and darunavir/ritonavir
- Trial name
- NCT00774735
- Testing
- GSK1349572
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Drug Interactions
Open-Label, Multiple-Dose, Non-Randomized Study to Assess Drug-Drug Interactions of Proellex® in Female Subjects
This study will assess possible drug-drug interactions with specific isoenzymes over a total study duration of 6-8 weeks. Blood samples collected pre and post-dose, and urine samples collected post dose will be analyzed.
- Trial name
- NCT00741468
- Testing
- Proellex, CYP1A2 probe, CYP2C9 probe
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Repros Therapeutics Inc.
Drug Interactions, Healthy
A Drug Interaction Study of Folic Acid and Oral Contraceptive Tablets Containing Norgestimate (NGM) /Ethinyl Estradiol (EE) in Healthy Women.
The purpose of the study is to assess the effect of folic acid administration on the blood level and the breakdown products of OC study drug (250 mcg norgestimate[NGM]/35 mcg Ethinyl Estradiol [EE]) tablets.
- Conditions
- Drug Interactions, Healthy, Pharmacokinetics
- Trial name
- NCT00709982
- Testing
- Norgestimate; Ethinyl Estradiol; Folic acid
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Anesthesia, Sedation
A Study Evaluating Drug-Drug Interaction (DDI) Between HSK3486 Injectable Emulsion and Rifampin Capsules
This is a Phase I, single-center, open-label, randomized,two-way crossover, propofol-controlled, two-stage study evaluating the safety and pharmacokinetics/pharmacodynamics of IV maintenance dose and IV single loade dose plus…
- Trial name
- NCT03758469
- Testing
- HSK3486, rifampin , HSK3486
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Sichuan Haisco Pharmaceutical Group Co., Ltd
Advanced Solid Tumors, Excluding Breast Cancer
Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors.
This is a multi-center, open-label, single-sequence, crossover, drug-drug interaction (DDI) study to assess the effect of the CYP1A2 inhibitor, fluvoxamine, on the PK of dovitinib in patients with advanced solid tumors, excluding…
- Trial name
- CTKI258A2120 (NCT01700270)
- Testing
- dovitinib (TKI258), fluvoxamine
- Where
- 6 sites in United States, Denmark and 2 more
- Volunteers
- 45 people
- Sponsor
- Novartis Pharmaceuticals
Healthy Adult Participants
Drug-drug Interactions Studies of VC005 Tablets in Healthy Adult Subjects
This study includes three groups of Drug-Drug Interaction( DDI ) studies: 1. To evaluate the effect of verapamil on the pharmacokinetics of a single oral dose of VC005 in healthy subjects; 2.
- Trial name
- NCT07796191
- Testing
- VC005 and verapamil, VC005 and probenecid, VC005 and metformin
- Where
- China
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Biological Availability
Drug-drug Interaction (DDI) Study to Assess ODM-201 as a Victim of CYP3A4 Inhibition or Induction
Evaluate the effect of a probe CYP3A4 inhibitor and inducer on the pharmacokinetics of BAY1841788 (ODM-201)
- Trial name
- NCT03048110
- Testing
- BAY1841788 (ODM-201), Itraconazole, Rifampicin
- Where
- Germany
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Bayer
Sickle Cell Disease
Drug Interaction Study of GBT440 With Caffeine, S-warfarin, Omeprazole, and Midazolam in Healthy Subjects
The purpose of this study to evaluate the effect of concomitant administration of GBT440 on caffeine (a CYP1A2 probe substrate), S warfarin (a CYP2C9 probe substrate), omeprazole (a CYP2C19 probe substrate), and midazolam (a…
- Trial name
- NCT02567682
- Testing
- GBT440
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Global Blood Therapeutics
Cholestasis
Linerixibat and Obeticholic Acid Drug Interaction Study in Healthy Subjects
In participants with inadequate response/intolerance to ursodeoxycholic acid (UDCA) taking obeticholic acid (OCA) who experience pruritus (due to primary biliary cholangitis [PBC], OCA, or both) the addition of linerixibat to OCA…
- Trial name
- NCT04053023
- Testing
- GSK2330672 (linerixibat), Obeticholic acid
- Where
- United Kingdom
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics, Pharmacodynamics, and Safety of Glyburide in Healthy Volunteers
The purpose of this study is to determine how multiple doses of canagliflozin (JNJ-28431754) affect the pharmacokinetics (ie, how the body affects the drug) and pharmacodynamics (ie, how the drug affects the body) of a single…
- Trial name
- NCT01733108
- Testing
- Glyburide, Canagliflozin (JNJ-28431754)
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Healthy
A Drug-drug Interaction Study to Investigate the Pharmacokinetic Interactions Between CKD-508, Midazolam, and Rosuvastatin in Healthy Adult Male Participants
Phase 1, open-label, non-randomized, three-treatment, one-sequence interaction study to evaluate the PK interactions between CKD-508, midazolam, and rosuvastatin in healthy adult male participants
- Trial name
- NCT06979973
- Testing
- Midazolam, Rosuvastatin, CKD-508 Tablet
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Healthy
A Drug-Drug Interaction Study to Estimate the Effect of PF-07081532 on the Pharmacokinetics of Dabigatran and Rosuvastatin in Overweight or Obese Adult Participants
The purpose of the study was to understand the effect of PF-07081532 on the movement of Dabigatran and Rosuvastatin into, though, and out of the body in healthy overweight or obese adult participants.
- Trial name
- NCT05788328
- Testing
- Dabigatran etexilate (DE), Rosuvastatin, PF-07081532
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Volunteer
A Drug-Drug Interaction Study Between PF-06882961 and PF-06865571 in Healthy Adult Participants and Overweight Adults or Adults With Obesity Who Are Otherwise Healthy
This study will be conducted in 2 parts. Part A will investigate the potential effect of PF-06865571 on the pharmacokinetics (PK) of PF-06882961 in healthy adult participants.
- Trial name
- NCT04839393
- Testing
- PF-06882961 followed by PF-06882961/PF-06865571, PF-06882961/PF-06865571 followed by PF-06882961, PF-06882961 + PF-06865571
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Pfizer
Infection, Human Immunodeficiency Virus I
A Drug Interaction Study Evaluating Plasma GSK2248761 and GSK1349572 Pharmacokinetics in Healthy Adult Subjects.
This is a single-center, open-label, three-period, fixed-sequence cross over study in healthy adult subjects. A total of approximately 16 healthy subjects will be enrolled to provide data from 12 evaluable subjects.
- Trial name
- NCT01283100
- Testing
- GSK1349572, GSK2248761
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Atherosclerosis
Study to Determine the Effect of Repeated Administration of Diltiazem on the Pharmacokinetics of Darapladib (Sb-480848).
Darapladib (SB-480848) is a novel, selective, orally active inhibitor of lipoprotein associated phospholipase A2 (Lp-PLA2) currently under clinical development by GlaxoSmithKline as a potential anti-atherosclerosis agent for…
- Trial name
- NCT01852565
- Testing
- Darapladib, Diltiazem
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Solid Tumors
A Study in People With Advanced Cancer to Test Whether the Amount of BI 907828 in the Blood is Influenced by Taking an OATP Inhibitor or a CYP3 Inhibitor
This study is open for adults with advanced cancer (solid tumours). This is a study for people for whom previous treatment was not successful. This study tests a medicine called BI 907828.
- Trial name
- NCT05372367
- Testing
- BI 907828, Rifampicin, Itraconazole
- Where
- 7 sites in Belgium, Spain
- Volunteers
- 33 people
- Sponsor
- Boehringer Ingelheim
Clinical Trial ,Phase I
Drug-drug Interaction Study: Influence of Vilaprisan on Pharmacodynamics (PD) and Pharmacokinetics (PK) of a Combined Oral Contraceptive (COC)
This study will be performed as a multi-center, randomized, double-blind study in 60 healthy women (2 groups of 30 women) to investigate ovarian activity during simultaneous intake of a COC (containing the estrogen EE and the…
- Trial name
- NCT03210246
- Testing
- Vilaprisan (BAY 1002670), Microgynon
- Where
- 2 sites in Germany
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Bayer
Healthy Participants
A Study to Assess the Effect of Multiple Doses of Itraconazole, Gemfibrozil, or Carbamazepine on BMS-986278 in Healthy Participants
This is a study in healthy participants designed to assess the effect of multiple doses of itraconazole, gemfibrozil, or carbamazepine on the drug levels of a single-dose of BMS-986278.
- Trial name
- NCT05932303
- Testing
- BMS-986278, Itraconazole, Gemfibrozil
- Where
- Canada
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Healthy
Drug-Drug Interaction Potential of Orbactiv (Oritavancin) Co-Administered With Warfarin in Healthy Subjects
The purpose of this study is to assess the drug interaction potential and time course of the effect of oritavancin on warfarin pharmacokinetics in an open label, single arm manner.
- Trial name
- NCT02340988
- Testing
- Single-Dose IV Oritavancin Diphosphate and Warfarin, Single-Dose IV Oritavancin Diphosphate and Warfarin 24 hour post dose
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Melinta Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.